Business
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep
About this update from Kyverna Therapeutics, Inc.
[{"type":"text","content":"Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval experience to support Kyverna’s next phase of growth EMERYVILLE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors. Mr. Emany will assume the role of Audit Committee Chair, following the transition of Dan Spiegelman from this position, who has stepped down from the Board. “We are pleased to welcome Sravan and Andrew to our Board of Directors at a pivotal moment in Kyverna’s evolution,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. “Sravan brings decades of financial and strategic leadership, with experience building and scaling rare disease cell and gene companies for commercial success. Additionally, Andrew has a proven track record as an R&D and operational leader across every stage of a company’s lifecycle. I look forward to working closely with both of them as we lead the advancement of autoimmune CAR T and position Kyverna for long-term success.” “Sravan and Andrew strengthen the Board as Kyverna enters its next phase of growth, bringing experience in capital strategy, clinical development, and operations to support long-term value creation,” said Christi Shaw, Executive Chair of Kyverna Therapeutics. “I would also like to thank Dan Spiegelman for his contributions during Kyverna’s formative years.” Mr. Emany is an accomplished financial leader, currently serving as the Chief Financial Officer (CFO) of Beam Therapeutics. Prior to this role, Mr. Emany served as the CFO and Chief Operating Officer at Ironwood Pharmaceuticals. Earlier, he served as Corporate Vice President, Commercial Excellence and Chief Strategy Officer of Integra LifeSciences Holdings Corporation. Mr. Emany also has a long tenure in investment banking, with roles of increasing responsibility at Bank of America and BofA Securities, formerly Bank of America Merrill Lynch, culminating in his service as Managing Director in the mergers and acquisitions group, where he led numerous mergers and acquisition...